JP2015524403A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015524403A5 JP2015524403A5 JP2015522106A JP2015522106A JP2015524403A5 JP 2015524403 A5 JP2015524403 A5 JP 2015524403A5 JP 2015522106 A JP2015522106 A JP 2015522106A JP 2015522106 A JP2015522106 A JP 2015522106A JP 2015524403 A5 JP2015524403 A5 JP 2015524403A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fusion protein
- domain
- functional fragment
- extracellular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020001507 fusion proteins Proteins 0.000 claims 13
- 102000037865 fusion proteins Human genes 0.000 claims 13
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims 5
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 5
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 3
- 239000003623 enhancer Substances 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12176978 | 2012-07-18 | ||
| EP12176980 | 2012-07-18 | ||
| EP12176978.0 | 2012-07-18 | ||
| EP12176980.6 | 2012-07-18 | ||
| PCT/EP2013/065248 WO2014013037A1 (en) | 2012-07-18 | 2013-07-18 | Shortened cd95-fc variants |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015524403A JP2015524403A (ja) | 2015-08-24 |
| JP2015524403A5 true JP2015524403A5 (enExample) | 2016-08-12 |
| JP6317739B2 JP6317739B2 (ja) | 2018-04-25 |
Family
ID=48794121
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015522107A Active JP6231562B2 (ja) | 2012-07-18 | 2013-07-18 | ＣＤ９５−Ｆｃアイソフォームの混合物を含む組成物 |
| JP2015522106A Expired - Fee Related JP6317739B2 (ja) | 2012-07-18 | 2013-07-18 | 短縮されたＣＤ９５−Ｆｃ変異体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015522107A Active JP6231562B2 (ja) | 2012-07-18 | 2013-07-18 | ＣＤ９５−Ｆｃアイソフォームの混合物を含む組成物 |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US9434783B2 (enExample) |
| EP (4) | EP2875044B1 (enExample) |
| JP (2) | JP6231562B2 (enExample) |
| KR (1) | KR102201694B1 (enExample) |
| CN (3) | CN104640876A (enExample) |
| AU (2) | AU2013291984B2 (enExample) |
| BR (1) | BR112015000732B1 (enExample) |
| CA (2) | CA2877989C (enExample) |
| DK (2) | DK2875045T3 (enExample) |
| ES (2) | ES2674662T3 (enExample) |
| HK (1) | HK1207095A1 (enExample) |
| IL (1) | IL236659A (enExample) |
| MX (1) | MX371430B (enExample) |
| NZ (1) | NZ703546A (enExample) |
| RU (2) | RU2648157C2 (enExample) |
| SG (1) | SG11201500134QA (enExample) |
| UA (1) | UA116889C2 (enExample) |
| WO (2) | WO2014013037A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2877989C (en) * | 2012-07-18 | 2021-05-25 | Apogenix Gmbh | Shortened cd95-fc variants |
| MX363679B (es) * | 2013-04-29 | 2019-03-29 | Apogenix Ag | Metodo para diagnosticar cancer. |
| NO2776305T3 (enExample) | 2014-04-23 | 2018-01-27 | ||
| EP3137909B1 (en) | 2014-04-29 | 2018-06-06 | Apogenix AG | Diagnostic anti-cd95l antibody |
| US9587215B2 (en) | 2014-08-07 | 2017-03-07 | General Electric Company | Devices, systems and methods for automated transfer of a sample |
| US20160176921A1 (en) * | 2014-12-22 | 2016-06-23 | Alexion Pharmaceuticals, Inc. | Methods of purifying recombinant proteins |
| CA3134144A1 (en) | 2019-03-29 | 2020-10-08 | Myst Therapeutics, Llc | Ex vivo methods for producing a t cell therapeutic and related compositions and methods |
| KR20220122639A (ko) | 2019-11-27 | 2022-09-02 | 미스트 쎄라퓨틱스, 엘엘씨 | 조절제를 이용한 종양 반응성 t 세포 조성물의 제조 방법 |
| JP7737374B2 (ja) * | 2019-12-12 | 2025-09-10 | イー・エム・デイー・ミリポア・コーポレイシヨン | 透析濾過緩衝液を用いて増強したウイルス濾過 |
| WO2021174208A1 (en) | 2020-02-27 | 2021-09-02 | Myst Therapeutics, Llc | Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof |
| KR102898622B1 (ko) * | 2020-04-10 | 2025-12-12 | 악스톤 바이오사이언시스 코퍼레이션 | Covid-19 융합 단백질에 대한 항원 특이적 면역요법 및 사용 방법 |
| CN115894706A (zh) * | 2021-09-30 | 2023-04-04 | 北京康辰药业股份有限公司 | 靶向PD-L1和FasL的融合蛋白、核苷酸序列及其应用 |
| WO2026044087A1 (en) | 2024-08-21 | 2026-02-26 | Shape Therapeutics Inc. | Increased cellular stability for aav production |
| WO2026073032A1 (en) | 2024-09-27 | 2026-04-02 | Shape Therapeutics Inc. | Constructs for improved aav production |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997042319A1 (en) * | 1996-05-02 | 1997-11-13 | Mochida Pharmaceutical Co., Ltd. | NOVEL Fas ANTIGEN DERIVATIVES |
| ATE273713T1 (de) * | 1996-10-31 | 2004-09-15 | Mochida Pharm Co Ltd | Fas-antagonist für die prophylaxe oder therapie von gvhd |
| KR20000075749A (ko) | 1997-02-27 | 2000-12-26 | 오노 야꾸힝 고교 가부시키가이샤 | 신규의 폴리펩티드, 그 폴리펩티드를 암호하는 ｄｎａ 및 그용도 |
| US6905684B1 (en) * | 1997-11-10 | 2005-06-14 | Mochida Pharmaceutical Co., Ltd. | Preventives and remedies for diffuse lung diseases |
| CN101684158A (zh) * | 2001-01-17 | 2010-03-31 | 特鲁比昂药品公司 | 结合域-免疫球蛋白融合蛋白 |
| EP1273297A1 (en) * | 2001-07-06 | 2003-01-08 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Vitamin E for the treatment of diseases in which the binding of the transcription factor NF-KB and/or AP-1 to promoter target sites has a beneficial effect (eg AIDS, cardiac infarction) |
| DK1606318T3 (da) * | 2003-03-26 | 2009-11-02 | Apogenix Gmbh | Forbedrede Fc-fusionsproteiner |
| WO2007109857A1 (en) * | 2006-03-28 | 2007-10-04 | Biopharmica Ltd | Agent for the treatment of hormone-dependent disorders and uses thereof |
| EP2041576B1 (en) * | 2006-06-21 | 2011-08-10 | Apogenix GmbH | Differential cytokine expression in human cancer |
| DK2101877T3 (da) * | 2006-12-28 | 2013-09-23 | Deutsches Krebsforsch | Neutralisering af virkningen af CD95 til blokering af invasion af glioblastomceller in vivo |
| WO2008101671A2 (en) * | 2007-02-19 | 2008-08-28 | Apogenix Gmbh | Il-4 fc fusion proteins |
| EP2009022A1 (en) * | 2007-06-26 | 2008-12-31 | Apogenix GmbH | Trimeric death ligands with enhanced activity (tenascin) |
| ES2524553T3 (es) * | 2008-06-17 | 2014-12-10 | Apogenix Gmbh | Receptores multiméricos de TNF |
| ES2593049T3 (es) * | 2009-01-09 | 2016-12-05 | Apogenix Ag | Proteínas de fusión que forman trímeros |
| WO2011010156A1 (en) * | 2009-07-21 | 2011-01-27 | Queen Mary & Westfield College | Fas (apo-1, cd95) targeted platforms for intracellular drug delivery |
| CN102770458A (zh) * | 2009-12-02 | 2012-11-07 | 阿塞勒隆制药公司 | 用于增加Fc融合蛋白的血清半寿期的组合物和方法 |
| CA2877989C (en) * | 2012-07-18 | 2021-05-25 | Apogenix Gmbh | Shortened cd95-fc variants |
| MX363679B (es) * | 2013-04-29 | 2019-03-29 | Apogenix Ag | Metodo para diagnosticar cancer. |
-
2013
- 2013-07-18 CA CA2877989A patent/CA2877989C/en not_active Expired - Fee Related
- 2013-07-18 JP JP2015522107A patent/JP6231562B2/ja active Active
- 2013-07-18 EP EP13737631.5A patent/EP2875044B1/en not_active Not-in-force
- 2013-07-18 SG SG11201500134QA patent/SG11201500134QA/en unknown
- 2013-07-18 HK HK15107778.6A patent/HK1207095A1/xx unknown
- 2013-07-18 AU AU2013291984A patent/AU2013291984B2/en active Active
- 2013-07-18 CA CA2878992A patent/CA2878992C/en active Active
- 2013-07-18 CN CN201380043661.6A patent/CN104640876A/zh active Pending
- 2013-07-18 WO PCT/EP2013/065248 patent/WO2014013037A1/en not_active Ceased
- 2013-07-18 UA UAA201500254A patent/UA116889C2/uk unknown
- 2013-07-18 BR BR112015000732-5A patent/BR112015000732B1/pt active IP Right Grant
- 2013-07-18 EP EP13742412.3A patent/EP2875045B1/en active Active
- 2013-07-18 ES ES13742412.3T patent/ES2674662T3/es active Active
- 2013-07-18 EP EP18166228.9A patent/EP3406630B1/en not_active Not-in-force
- 2013-07-18 RU RU2015105328A patent/RU2648157C2/ru active
- 2013-07-18 CN CN201380038208.6A patent/CN104662039B/zh not_active Expired - Fee Related
- 2013-07-18 WO PCT/EP2013/065250 patent/WO2014013039A1/en not_active Ceased
- 2013-07-18 CN CN201910254827.8A patent/CN109897115A/zh active Pending
- 2013-07-18 AU AU2013291982A patent/AU2013291982B2/en not_active Ceased
- 2013-07-18 JP JP2015522106A patent/JP6317739B2/ja not_active Expired - Fee Related
- 2013-07-18 DK DK13742412.3T patent/DK2875045T3/en active
- 2013-07-18 RU RU2015105330A patent/RU2648146C2/ru active
- 2013-07-18 US US14/415,871 patent/US9434783B2/en not_active Expired - Fee Related
- 2013-07-18 NZ NZ703546A patent/NZ703546A/en unknown
- 2013-07-18 DK DK18164139.0T patent/DK3409686T3/da active
- 2013-07-18 KR KR1020157004183A patent/KR102201694B1/ko active Active
- 2013-07-18 MX MX2015000731A patent/MX371430B/es active IP Right Grant
- 2013-07-18 ES ES18164139T patent/ES2924109T3/es active Active
- 2013-07-18 EP EP18164139.0A patent/EP3409686B1/en active Active
- 2013-07-18 US US14/415,866 patent/US9315570B2/en active Active
-
2015
- 2015-01-11 IL IL236659A patent/IL236659A/en active IP Right Grant
-
2016
- 2016-04-18 US US15/131,219 patent/US9657083B2/en active Active
- 2016-08-17 US US15/239,127 patent/US9908928B2/en not_active Expired - Fee Related
-
2018
- 2018-02-22 US US15/902,175 patent/US10370441B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015525217A5 (enExample) | ||
| JP2015212284A5 (enExample) | ||
| HRP20200871T1 (hr) | Izmjenjeni rsv f proteini i postupci njihove uporabe | |
| PE20191033A1 (es) | PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa) | |
| EA201291362A1 (ru) | Слитый белок против злокачественных новообразований | |
| WO2013040093A3 (en) | Glucagon-like peptide-2 compositions and methods of making and using same | |
| MX358725B (es) | Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden. | |
| WO2011123813A3 (en) | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same | |
| MX387465B (es) | Marcas genéticas de transgenes y métodos de uso. | |
| EA033386B1 (ru) | Рекомбинантные иммуногенные полипептиды стеблевого домена гемагглютинина вируса гриппа а и их применение | |
| EP3372617A3 (en) | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same | |
| BRPI1010880A2 (pt) | polipeptídeos de hormônio de crescimento e métodos de fazer e usar os mesmos. | |
| EP2470559A4 (en) | COAGULATION FACTOR IX COMPOSITIONS AND METHODS OF MAKING AND USING THEM | |
| NZ602943A (en) | Modified binding proteins inhibiting the vegf-a receptor interaction | |
| PE20190845A1 (es) | Metodos para determinar resistencia a terapia de receptor de androgeno | |
| PH12012502272A1 (en) | Biological materials related to her3 | |
| PE20190352A1 (es) | Proteinas de fusion gdf 15 y usos de estas | |
| WO2013151670A3 (en) | Modified polynucleotides for the production of nuclear proteins | |
| HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
| JP2013527765A5 (enExample) | ||
| JP2015504052A5 (enExample) | ||
| NZ629309A (en) | Tumour necrosis factor receptor fusion proteins and methods of using the same | |
| EA201491277A1 (ru) | Противораковый слитый белок | |
| WO2009024327A3 (en) | New proteins for use in human and animal staphylococcus infections | |
| EP2589658A4 (en) | PARTIAL REGION POLYPEPTIDE OF REIC / DKK-3 PROTEIN |